CapyFin

Calendar Reports Pricing

Search for a symbol...

Loading...

CapyFin Real-time Earnings Reports.

Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Privacy Policy
Terms of Service
Sign Up
Sign In

© 2026 CapyFin. All rights reserved.

Disclaimer: CapyFin provides financial data and AI analysis for informational purposes only and does not provide investment advice or recommendations. Real-time data and AI outputs may be inaccurate, incomplete, delayed, or contain errors or hallucinations. Investing involves risk, including loss of principal. The service is provided “as is” and we disclaim liability to the fullest extent permitted by law. See our Terms of Service and Privacy Policy.

NewAmsterdam Pharma Fiscal Q4 2023 Earnings Report | CapyFin

NewAmsterdam Pharma

NAMS · NASDAQ🇳🇱

Overview Earnings

Dividends Seasonality Metrics

Q1 2026 in 1mo Q4 2025 -3.05%Q3 2025 +4.33%Q2 2025 +8.75%Q1 2025 +1.25%Q4 2024 +10.23%Q3 2023 +18.22%Q3 2024 +18.22%Q2 2024 +4.19%Q1 2024 -9.64%Q2 2023 -5.74%Q4 2023 -5.74%Q1 2023 +0.28%Q4 2021 +2.11%Q4 2022 +2.11%Q3 2022 -0.10%Q2 2022 +0.10%Q1 2022 0.00%Q3 2021 -0.31%Q2 2021 +0.20%Q1 2021 +0.10%Q4 2020 Q3 2020 Q2 2020 Q1 2020

Feb 28, 2024

•

Dec 31, 2023

NewAmsterdam Pharma Q4 2023 Earnings Report

Previous year: $103M

Previous year: -$1.19

Research and Development Expenses

Selling, General and Administrative Expenses

Total Operating Expenses

Previous year: $1.38M

Previous year: $478M

NewAmsterdam Pharma

Unlock previous datapoints

NewAmsterdam Pharma

Unlock previous datapoints

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...

Company Overview

Full financial data and analysis

View NewAmsterdam Pharma